Equivalency of Multiple Biomarkers to Clinical Pulmonary Arterial Hypertension Survival Risk Models

Risk assessment in pulmonary arterial hypertension (PAH) is fundamental to guiding treatment and improved outcomes. Clinical models are excellent at identifying high-risk patients, but leave uncertainty amongst moderate-risk patients.